Last reviewed 2026-04-20 · How we verify

Methoxamin (METHOXAMINE)

Methoxamine, also known as Methoxamine, is a small molecule drug developed by GlaxoSmithKline that targets the alpha-1A adrenergic receptor. It is used to treat low blood pressure and paroxysmal supraventricular tachycardia. As an off-patent medication, it is no longer protected by active patents, but its generic status is uncertain due to the lack of generic manufacturers. Methoxamine works by stimulating the alpha-1A adrenergic receptor, which increases blood pressure and heart rate. It is a valuable treatment option for patients with these conditions, but its commercial status and availability may be limited.

At a glance

Approved indications

• Low blood pressure
• Paroxysmal supraventricular tachycardia

Common side effects

No common side effects on file.

Key clinical trials

• The Safety and Dose Response to Single Anal Doses of NRL001 (PHASE1)
• Safety and Tolerability of the Twice Daily Intra-anal Application of NRL001 Cream for 14 Days (PHASE1)
• A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period (PHASE2)
• Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001. (PHASE1)
• Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or Rectum (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.